As a matter of fact, driver variants in SMO and PTCH1 are considered to be predictive biomarkers for the response of BCC patients to the treatment with Vismodegib [27] (Hh pathway inhibitor). The gene discussed is SMO; the disease is skin basal cell carcinoma.